Basic Information
MYOVIEW FOR INJECTION 0.23 mg/vial
INJECTION, POWDER, FOR SOLUTION
Regulatory Information
SIN11820P
February 25, 2002
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
May 30, 2025
XV09GA02
Company Information
Active Ingredients
Strength: 0.23 mg/vial
Detailed Information
Contraindications
**Contra-indications** Myoview is contraindicated in pregnancy and in patients with known hypersensitivity to tetrofosmin or any of the excipients.
Indication Information
**Indications** This medicinal product is for diagnostic use only. _Myocardial Imaging:_ Myoview is a myocardial perfusion agent indicated as an adjunct in the diagnosis and localization of myocardial ischaemia and/or infarction. _Breast Tumour Imaging:_ Myoview is indicated as an adjunct to the initial assessments (e.g palpation, mammography, or alternative imaging modalities and/or cytology) in the characterisation of malignancy of suspected breast lesions where all these other recommended tests were inconclusive.